Is PDS Biotechnology Corporation (PDSB) a Buy, Sell, or Hold?
NASDAQ : PDSB
PDS Biotechnology Corporation — News
$0.2568 USD
-$0.47 (-64.87%)
- Volume
- 26.75M
- Average Volume
- 795.78K
- Market Capitalization
- $14.36M
- P/E Ratio
- -0.38
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $1.55
- Year Low
- $0.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.26
| Source | Headline |
|---|---|
|
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer. benzinga.com - 2026-08-11 13:49:42 |
|
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immunotherapies for cancer, today issued a Letter to Shareholders from Frank Bedu-Addo, Ph.D. globenewswire.com - 2026-08-11 08:25:00 |
|
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. zacks.com - 2026-06-10 10:56:11 |
|
PDS Biotechnology Q1 Earnings Call Highlights
PDS Biotechnology NASDAQ: PDSB reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs. marketbeat.com - 2026-05-13 14:11:12 |
|
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-13 10:10:43 |
|
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026. globenewswire.com - 2026-05-13 07:00:00 |
